Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Current Deferred Revenue (2016 - 2024)

Rockwell Medical's Current Deferred Revenue history spans 15 years, with the latest figure at $475000.0 for Q4 2024.

  • For Q4 2024, Current Deferred Revenue rose 932.61% year-over-year to $475000.0; the TTM value through Dec 2024 reached $475000.0, up 932.61%, while the annual FY2024 figure was $475000.0, 932.61% up from the prior year.
  • Current Deferred Revenue reached $475000.0 in Q4 2024 per RMTI's latest filing, up from $46000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $11.6 million in Q1 2020 to a low of $46000.0 in Q3 2023.
  • Average Current Deferred Revenue over 5 years is $3.6 million, with a median of $2.2 million recorded in 2020.
  • Peak YoY movement for Current Deferred Revenue: skyrocketed 84852.53% in 2020, then tumbled 99.32% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $2.2 million in 2020, then soared by 275.03% to $8.2 million in 2021, then plummeted by 46.9% to $4.3 million in 2022, then tumbled by 98.94% to $46000.0 in 2023, then skyrocketed by 932.61% to $475000.0 in 2024.
  • Per Business Quant, the three most recent readings for RMTI's Current Deferred Revenue are $475000.0 (Q4 2024), $46000.0 (Q3 2024), and $498000.0 (Q2 2024).